PRTN3 and rheumatoid arthritis: The proportion of biologic-naïve patients with CDAI and SDAI remission was 24.3% and 24.3% (RF/ACPA double-positive RA) and 8.9% and 9.1% (RF/ACPA double-negative RA), respectively (Fig. 4B).